LSD, Molly, and MDMA: What Pakistani Parents Need to Know About Designer Drugs

A few years ago, most Pakistani families had never heard of LSD, Molly, or MDMA. These were drugs associated with foreign cities, Western nightlife, and news stories that felt distant. That distance no longer exists.

These substances are now present in Pakistani urban centres. They circulate in university environments, at private gatherings, and through social networks that are often invisible to parents. They are increasingly accessible, and they are being used by young people whose families have no idea what these drugs are, what they do, or what the warning signs look like.

This article is written for those families. It explains what each of these substances is, how they affect the brain and body, what the risks are, and what to do if you believe someone you care about is using them.

What are designer drugs?

Designer drugs is a broad term for synthetic or semi-synthetic psychoactive substances that are created to mimic the effects of established controlled drugs, often by making small chemical modifications that allow them to evade legal classification. LSD, MDMA (Molly or Ecstasy), and related compounds fall broadly within this category, alongside a growing range of newer substances that arrive on the market continuously.

What makes these drugs particularly dangerous is the combination of their potency, the variability in what is actually sold under their names, and the fact that users often have little accurate information about what they are taking. A tablet sold as Molly or Ecstasy in Pakistan may contain MDMA, a range of other substances, no MDMA at all, or a combination that includes genuinely dangerous adulterants. This unpredictability makes every use a significant risk.

LSD: what it is and what it does

LSD, or lysergic acid diethylamide, is a powerful hallucinogenic drug derived from ergot, a fungus that grows on certain grains. It was first synthesised in 1938 and became widely used in the 1960s. It has no approved medical use and is classified internationally as a Schedule I controlled substance under the United Nations drug conventions.

LSD is typically sold on small squares of paper called blotter tabs, on sugar cubes, or in liquid form. The doses involved are measured in micrograms, making it one of the most potent psychoactive substances by weight. A quantity invisible to the naked eye is sufficient to produce powerful effects lasting eight to twelve hours.

What LSD does to the brain and body:

LSD acts primarily on serotonin receptors in the brain, producing profound alterations in perception, thought, and emotion. The experience includes intense visual and auditory hallucinations, distorted sense of time and self, and emotional states that can swing between euphoria and overwhelming terror within the same experience.

The physical effects include dilated pupils, elevated heart rate and blood pressure, increased body temperature, loss of appetite, and sleeplessness. These effects are not trivial, particularly in individuals with underlying cardiac or psychiatric conditions.

The specific risks of LSD:

Bad trips are common and can be genuinely traumatic. During a difficult LSD experience, a person may be convinced they are dying, losing their mind, or trapped in a reality that has broken apart. This can lead to dangerous behaviour including self-harm or accidents, particularly if the person is not in a safe environment with trusted companions.

Hallucinogen Persisting Perception Disorder (HPPD) is a recognised condition in which a person continues to experience visual disturbances, such as trails, halos, and geometric patterns, long after the drug has been used. For some individuals this persists for months or years. It is distressing, there is no reliable treatment, and it can significantly impair daily functioning.

LSD is not considered physically addictive in the same way as heroin or methamphetamine. However, psychological dependency can develop, and the disruption it causes to mental health, particularly in young people or those with pre-existing vulnerabilities, can be severe and lasting.

MDMA: what it is and what it does

MDMA, or 3,4-methylenedioxymethamphetamine, is a synthetic psychoactive drug that acts as both a stimulant and a mild hallucinogen. It is known by a range of street names including Ecstasy, E, and Molly, though these terms are often used loosely and the substance sold under them is frequently adulterated or entirely different.

MDMA was synthesised in the early twentieth century and was used experimentally in psychotherapy settings before being placed under international control. It has no approved medical use in Pakistan. It typically comes in tablet or capsule form and is taken orally, though it is sometimes snorted.

What MDMA does to the brain and body:

MDMA causes a massive release of serotonin, dopamine, and norepinephrine simultaneously. This produces the characteristic effects users seek: intense feelings of emotional warmth and closeness to others, heightened sensory experience, euphoria, and increased energy. These effects typically last three to six hours.

The physical effects include raised heart rate and blood pressure, increased body temperature, jaw clenching and teeth grinding, nausea, and blurred vision. In high doses or in warm environments with physical activity, MDMA can cause dangerous overheating. A number of deaths internationally have been directly attributed to hyperthermia and hyponatremia (dangerous drop in blood sodium) associated with MDMA use, as documented by the World Health Organization.

What is Molly?

Molly is a street name that originally referred to a supposedly purer, powder or crystal form of MDMA, as opposed to Ecstasy tablets. In practice, substances sold as Molly are frequently adulterated with other compounds including methamphetamine, cathinones (bath salts), or a range of research chemicals. The name carries no guarantee of content. Laboratory testing of substances sold as Molly internationally has consistently shown a high rate of adulteration.

The specific risks of MDMA:

The serotonin depletion that follows MDMA use produces what users commonly call the “comedown” or “Tuesday blues” after weekend use: a period of depression, anxiety, irritability, and cognitive impairment that can last several days. With repeated use, this depletion becomes more pronounced and recovery takes longer.

Research published by NIDA indicates that heavy MDMA use is associated with long-term changes in serotonin-producing neurons, impaired memory and attention, and increased vulnerability to depression and anxiety disorders. In young people whose brains are still developing, these effects are more pronounced and the risk of lasting harm is greater.

How these drugs are reaching Pakistani youth

The routes through which LSD, MDMA, and related substances reach Pakistan are multiple. International trafficking networks supply the primary compounds. But the spread within Pakistan happens largely through social networks, often facilitated by messaging applications and a social environment in which these substances are discussed in terms that make them sound safe, sophisticated, or even therapeutic.

A significant factor is the framing of these drugs in international popular culture, social media, and wellness discourse. LSD and MDMA have received positive coverage in some media contexts in recent years, framed as tools for mental health, creativity, or spiritual growth. This framing is not representative of the reality for most users, particularly in a context without medical supervision, reliable dosing, or quality control. Young people encountering these narratives without accurate counter-information are poorly equipped to assess the actual risk.

Parents often know less than their children about these substances. This information gap is one of the most significant risk factors.

Warning signs in young people

Because designer drugs like LSD and MDMA are typically used episodically rather than daily, the signs can be harder to spot than with substances used more continuously. The following changes are worth paying attention to.

After use:

• Unusual emotional intensity or warmth immediately after spending time with friends, followed by a period of low mood, withdrawal, and irritability in the days that follow
• Jaw soreness or clenching
• Dilated pupils, particularly in the evening or after returning home
• Unusual sweating or complaints of body temperature changes
• Significant disruption to sleep

Patterns over time:

• Increasing secrecy around social activities and friendships
• New social circles that exclude family contact
• Declining academic or professional performance
• Growing expressions of depression, anxiety, or emotional flatness between periods of apparent high energy and sociability
• Financial changes, particularly unexplained spending

Psychological changes:

• Unusual philosophical or perceptual statements, particularly after LSD use, such as comments about reality feeling strange, time distorting, or visual experiences that seem odd
• Increased anxiety or paranoia
• Signs of a developing mental health condition, including persistent low mood, dissociation, or perceptual disturbances that persist beyond the period of suspected drug use

The risk of psychosis and mental health crisis

This is the area where parental concern is most warranted and where early action matters most.

Both LSD and MDMA carry a meaningful risk of triggering psychotic episodes, particularly in individuals with a personal or family history of psychiatric illness. Psychosis can be precipitated by a single use in a vulnerable individual. It can also emerge gradually with repeated use. In either case, it is a psychiatric emergency that requires prompt professional assessment and treatment.

The challenge for families is that the onset of a drug-induced mental health crisis can be difficult to distinguish from the emergence of a primary psychiatric condition. The distinction matters for treatment. What does not require distinction is the need to seek help quickly. If a young person is showing signs of psychosis including paranoid thinking, auditory hallucinations, severely disordered behaviour, or significant disconnection from reality, clinical assessment should not be delayed.

Our Dual Diagnosis Programme is designed precisely for situations in which a mental health condition and substance use are present together and need to be treated as an integrated clinical picture rather than separately.

What to do if you suspect your child is using these drugs

The most important first step is not confrontation but information. Going into a conversation without understanding what these substances are, what they do, and how addiction works puts the conversation at a disadvantage from the start.

Approach the conversation with genuine concern rather than anger. Young people who feel attacked become defensive. Young people who feel that a parent is genuinely trying to understand are more likely to engage honestly.

If use is confirmed or strongly suspected, a clinical assessment is the appropriate next step. An assessment by a qualified addiction psychiatrist or clinical psychologist will establish what substances have been used, at what level, over what period, and whether there are co-occurring mental health concerns that need attention. It provides a factual foundation for decisions about what kind of support is needed.

Our Family Support Programme provides structured guidance for families navigating exactly this situation. Many families find that they need as much support in understanding what is happening and how to respond as the young person needs in treatment.

Treatment for designer drug use and addiction

Treatment needs vary significantly depending on the substance, the pattern of use, and whether co-occurring mental health conditions are present.

Assessment and diagnosis is always the first step. The variability in what is actually being used, and the frequency with which designer drug use co-occurs with mental health conditions or the use of other substances, means that treatment cannot be appropriately designed without a thorough clinical picture.

Psychological intervention is the primary treatment for LSD and MDMA-related addiction. There is no medication specifically approved for either substance. Cognitive Behavioural Therapy addresses the thought patterns and behaviours associated with use. Motivational Enhancement Therapy works with ambivalence, which is often high in younger users who do not yet fully accept that their use has become problematic.

Psychiatric treatment for co-occurring conditions is integrated into our clinical approach. Depression, anxiety disorders, and psychotic symptoms that have been unmasked or triggered by designer drug use all require direct treatment. Addressing the mental health condition and the substance use together, rather than sequentially, produces significantly better outcomes.

Residential rehabilitation is appropriate where use is frequent, where co-occurring mental health concerns are significant, or where the young person’s home and social environment makes sustained recovery unlikely without a period of structured residential care. Our Drug Addiction Treatment Programme offers 30, 60, and 90-day residential options and is staffed by a clinical team that includes consultant psychiatrists, clinical psychologists, and public health specialists.

Family involvement throughout treatment is not optional. It is one of the strongest predictors of long-term recovery, particularly for young people. The family system that the young person returns to after treatment has an enormous influence on whether recovery is sustained or undermined.

When to seek help

If you are reading this because you are concerned about a young person in your family, acting early is always better than waiting. Designer drug use among young people does not reliably self-correct. The risk of escalation, of a mental health crisis, and of entrenched dependency all increase with time.

A confidential clinical assessment carries no commitment and no judgement. It will give you an accurate picture of the situation and honest guidance on what level of support, if any, is needed. Contact us today to speak with a member of our clinical team, WhatsApp us if you prefer to reach out privately, or call us directly to arrange an assessment.